Last updated: February 22, 2026
CESAMET (Cisplatin and Etoposide) is an anticancer medication used primarily for lung and testicular cancers. It comprises a combination of cisplatin, a platinum-based compound, and etoposide, a topoisomerase inhibitor. Availability depends on generic and branded manufacturers, with several suppliers globally.
Major Suppliers and Manufacturers
| Supplier |
Region |
Product Availability |
Notes |
| APP Pharmaceuticals |
North America |
Approved generic versions |
Supplies hospital and compounding pharmacies |
| Fresenius Kabi |
Global |
Commercial and generic versions |
Offers both brand and generic formulations |
| Hospira (Pfizer) |
Global |
Generic version |
Marketed as Cisplatin in various regions |
| Sun Pharmaceutical Industries |
India |
Generic forms |
One of the largest producers of sterile oncology injectables |
| Dr. Reddy’s Laboratories |
India |
Generic versions |
Supplies in multiple markets, including the US |
| Cipla |
India |
Generic supply |
Focuses on affordable oncology formulations |
| Natco Pharma |
India |
Generic supply |
Also markets in the US and Europe |
| Fresenius Kabi |
Multiple regions |
Commercial product |
Offers cisplatin formulations |
Regulatory Approvals and Market Access
- United States: FDA-approved versions mainly through Hospira (now part of Pfizer) and generic manufacturers like Sun Pharma and Dr. Reddy’s.
- Europe: Approved by EMA with several generics available from Indian manufacturers.
- India: Multiple local manufacturers, including Cipla, Natco Pharma, and Sun Pharma, distribute both branded and generic versions.
- Other Regions: Approval varies by country, with local pharmaceutical authorities permitting imports and local manufacturing.
Sourcing Considerations
- Formulation: Mainly supplied as intravenous solution, requiring cold storage.
- Quality standards: Options include U.S. Pharmacopeia (USP), European Pharmacopoeia (EP), and local regulatory standards.
- Supply chain: Limited global suppliers could lead to shortages; manufacturing disruptions documented during the COVID-19 pandemic affected availability.
Market Dynamics and Competition
- Generic manufacturers dominate due to the expiration of patent exclusivity for some formulations.
- price competition exists among Indian and international generic suppliers.
- New entrants face regulatory hurdles, including biosimilar or alternative combination therapies.
Key Takeaways
- Multiple suppliers worldwide provide CESAMET’s components, mainly generic manufacturers.
- Availability varies by region, with Indian companies playing a significant role in global supply.
- Regulatory approval status influences geographic access.
- Supply chain disruptions, including during health crises, impact sourcing.
- Quality standards are consistent with regional pharmacopoeias, but buyers should verify compliance.
FAQs
1. Who are the primary suppliers of cisplatin, a component of CESAMET?
Major suppliers include Fresenius Kabi, Sun Pharmaceutical Industries, and Hospira. Indian companies like Sun Pharma and Cipla also produce cisplatin for global markets.
2. Are there authorized generic versions of CESAMET available in the US?
Yes. Generic cisplatin and etoposide are available from multiple companies, including Sun Pharma and Dr. Reddy’s Laboratories, approved by the FDA.
3. What are the considerations for sourcing CESAMET internationally?
Regulatory approval, formulation standards, supplier reliability, and storage requirements determine sourcing options.
4. How has the COVID-19 pandemic affected the supply of CESAMET?
Disruptions in manufacturing and distribution caused temporary shortages, especially among Indian generic suppliers.
5. Can hospitals or pharmacies compound CESAMET?
Compounding is possible in regulated environments with approved sterile procedures, but most entities prefer licensed ready-to-administer formulations.
Sources
- U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations.
- European Medicines Agency. (2022). Market authorization for oncology medications.
- Indian Pharmacopoeia Commission. (2021). List of notified pharmaceutical manufacturers.
- Pharmaceutical Technology. (2022). COVID-19 impact on anticancer drug supply chains.
- National Comprehensive Cancer Network. (2023). Treatment guidelines for lung and testicular cancers.
